2. Academic Validation
  3. Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer

Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer

  • Pathol Res Pract. 2023 Feb 3;243:154352. doi: 10.1016/j.prp.2023.154352.
Fan Yang 1,  Peiwen Xu 1,  Surui Yao 1,  Min Li 2,  Zehua Bian 3,  Zhaohui Huang 4
Affiliations

Affiliations

  • 1 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
  • 2 Pharmacy Department, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu 214100, China.
  • 3 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China. Electronic address: [email protected].
  • 4 Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China. Electronic address: [email protected].
PMID: 36758416 DOI: 10.1016/j.prp.2023.154352
Abstract

Signaling receptor and transporter of retinol STRA6 (STRA6) plays a primary role in transporting retinol. Several studies have reported that STRA6 is involved in several pathways related to tumorigenesis and progression. However, the exact functions and mechanisms of STRA6 in colorectal Cancer (CRC) remain unclear. In our work, STRA6 was highly up-regulated in CRC and promoted the proliferation of CRC cells. Additionally, we discovered that STRA6 suppresses Apoptosis partly by controlling BCL2 expression, which in turn causes CRC to become resistant to LOHP treatment. Our study demonstrates that STRA6 is a potential prognostic factor and oncogene in CRC by promoting CRC growth and chemoresistance.

Keywords

Chemoresistance; Colorectal cancer; Oxaliplatin; Proliferation; STRA6.

Figures
Products